Immunology & Inflammation Therapeutics
Oblenio Bio: Products & infrastructure
Data updated Nov 20, 2026 · Back to the company report
Products
1EU trials (CTIS)
EU clinical trialsthe trials it sponsors, per the EU's CTIS register
A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease
Human Pharmacology (Phase I)- First administration to humans · B-cell–mediated autoimmune diseases · Germany, Romania, Poland
Jun 2026
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
